| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $96,933 | 3 | 13 |
Sells | $85,179 | 20 | 87 |
| Cowan Chad | Chief Scientific Officer | 1 | $49,252 | 1 | $2,736 | $46,516 |
| Pfeiffenberger Brent | President and CEO | 2 | $47,681 | 4 | $31,410 | $16,271 |
| Farid Adrienne | Chief Operations Officer | 0 | $0 | 2 | $907 | $-907 |
| Carr Douglas | SVP Finance & Operations | 0 | $0 | 8 | $22,351 | $-22,351 |
| Russotti Gregory | See Remarks | 0 | $0 | 5 | $27,775 | $-27,775 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $96,933 and sold $85,179 worth of Century Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $10.7M and sold $2.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cowan Chad (Chief Scientific Officer) — $49,252. Pfeiffenberger Brent (President and CEO) — $47,681.
The last purchase of 58,060 shares for transaction amount of $49,252 was made by Cowan Chad (Chief Scientific Officer) on 2025‑12‑22.
| 2026-03-12 | Sale | Russotti Gregory | See Remarks | 10,076 0.0118% | $2.55 | $25,684 | -8.60% | |
| 2026-03-12 | Sale | Carr Douglas | SVP Finance & Operations | 7,043 0.0082% | $2.55 | $17,953 | -8.60% | |
| 2026-03-09 | Sale | Russotti Gregory | See Remarks | 479 0.0005% | $2.54 | $1,215 | -22.28% | |
| 2026-02-03 | Sale | Carr Douglas | SVP Finance & Operations | 323 0.0004% | $1.82 | $589 | +22.01% | |
| 2025-12-22 | Cowan Chad | Chief Scientific Officer | 58,060 0.0666% | $0.85 | $49,252 | +151.48% | ||
| 2025-12-12 | Pfeiffenberger Brent | President and CEO | 52,000 0.0629% | $0.58 | $30,352 | +281.93% | ||
| 2025-12-08 | Sale | Carr Douglas | SVP Finance & Operations | 257 0.0003% | $0.53 | $137 | +261.40% | |
| 2025-12-08 | Sale | Russotti Gregory | See Remarks | 526 0.0006% | $0.53 | $280 | +261.40% | |
| 2025-11-20 | Sale | Cowan Chad | Chief Scientific Officer | 5,462 0.0065% | $0.50 | $2,736 | +310.64% | |
| 2025-11-19 | Pfeiffenberger Brent | President and CEO | 35,000 0.0387% | $0.50 | $17,329 | +288.86% | ||
| 2025-11-17 | Sale | Pfeiffenberger Brent | President and CEO | 32,456 0.0355% | $0.45 | $14,735 | +311.20% | |
| 2025-11-03 | Sale | Carr Douglas | SVP Finance & Operations | 292 0.0003% | $0.59 | $171 | +221.67% | |
| 2025-09-08 | Sale | Pfeiffenberger Brent | President and CEO | 488 0.0006% | $0.50 | $244 | +91.93% | |
| 2025-09-08 | Sale | Carr Douglas | SVP Finance & Operations | 263 0.0003% | $0.50 | $132 | +91.93% | |
| 2025-09-08 | Sale | Russotti Gregory | See Remarks | 539 0.0006% | $0.50 | $270 | +91.93% | |
| 2025-08-04 | Sale | Carr Douglas | SVP Finance & Operations | 296 0.0003% | $0.53 | $158 | +4.74% | |
| 2025-06-09 | Sale | Pfeiffenberger Brent | President and CEO | 475 0.0005% | $0.62 | $295 | -6.81% | |
| 2025-06-09 | Sale | Carr Douglas | SVP Finance & Operations | 4,904 0.0056% | $0.62 | $3,050 | -6.81% | |
| 2025-06-09 | Sale | Russotti Gregory | See Remarks | 526 0.0006% | $0.62 | $327 | -6.81% | |
| 2025-06-09 | Sale | Farid Adrienne | Chief Operations Officer | 552 0.0006% | $0.62 | $343 | -6.81% |
| Pfeiffenberger Brent | President and CEO | 3322990 3.8385% | $8.61M | 2 | 6 | |
| Cowan Chad | Chief Scientific Officer | 1045087 1.2072% | $2.71M | 1 | 1 | |
| Russotti Gregory | See Remarks | 515427 0.5954% | $1.33M | 0 | 14 | |
| Carr Douglas | SVP Finance & Operations | 507261 0.586% | $1.31M | 0 | 15 | |
| Farid Adrienne | Chief Operations Officer | 250141 0.2889% | $647,865.19 | 0 | 12 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 12675838 14.6424% | $32.83M | 1 | 0 | <0.0001% |
| Versant Vantage II GP-GP, LLC | 11816814 13.6501% | $30.61M | 0 | 1 | ||
| Casdin Eli | director | 3206380 3.7038% | $8.3M | 1 | 0 | <0.0001% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 714095 0.8249% | $1.85M | 1 | 0 | <0.0001% |
| Borges Luis | Chief Scientific Officer | 249083 0.2877% | $645,124.97 | 0 | 3 | |
| Quimi Daphne | director | 5000 0.0058% | $12,950.00 | 1 | 0 | <0.0001% |
$8,708,580 | 93 | -5.38% | $225.18M | |
$8,712,825 | 57 | 2.45% | $223.54M | |
$18,752,549 | 33 | -28.39% | $208.74M | |
$6,915,275 | 21 | -32.61% | $201.05M | |
$38,821,584 | 20 | -2.17% | $223.72M | |
$245,302 | 15 | -4.08% | $230.62M | |
$1,037,470 | 13 | 78.00% | $245.01M | |
$15,799,576 | 12 | -39.52% | $197.83M | |
$344,394 | 8 | -22.26% | $212.6M | |
$145,296,407 | 8 | -0.98% | $240.19M | |
$164,999,952 | 5 | -44.44% | $224.92M | |
$36,049,976 | 5 | -3.82% | $239.43M | |
$556,839 | 5 | 13.42% | $239.37M | |
$20,729,984 | 5 | 51.71% | $252.98M | |
Century Therapeutics, Inc. (IPSC) | $32,007,657 | 4 | -45.65% | $224.21M |
$16,003,671 | 3 | 55.38% | $220.23M | |
$193,101 | 3 | -25.20% | $206.25M | |
$12,498 | 2 | 39.61% | $240.94M | |
$63,731 | 1 | -19.50% | $194.35M |
| Increased Positions | 17 | +21.25% | 12M | +59.9% |
| Decreased Positions | 32 | -40% | 7M | -33.16% |
| New Positions | 8 | New | 9M | New |
| Sold Out Positions | 16 | Sold Out | 5M | Sold Out |
| Total Postitions | 65 | -18.75% | 26M | +26.74% |
| Bain Capital Life Sciences Investors, Llc | $3,521.00 | 4.07% | 3.54M | -2M | -34.6% | 2025-09-30 |
| Renaissance Technologies Llc | $2,574.00 | 2.97% | 2.59M | +564,400 | +27.91% | 2025-09-30 |
| Vanguard Group Inc | $2,093.00 | 2.42% | 2.1M | -6,213 | -0.29% | 2025-09-30 |
| Dafna Capital Management Llc | $1,696.00 | 1.96% | 1.7M | 0 | 0% | 2025-09-30 |
| Casdin Capital, Llc | $1,222.00 | 1.41% | 1.23M | 0 | 0% | 2025-09-30 |
| Syncona Portfolio Ltd | $1,207.00 | 1.39% | 1.21M | 0 | 0% | 2025-09-30 |
| Two Sigma Investments, Lp | $907.00 | 1.05% | 911,446 | +338,902 | +59.19% | 2025-09-30 |
| Tang Capital Management Llc | $896.00 | 1.03% | 900,000 | 0 | 0% | 2025-09-30 |
| Two Sigma Advisers, Lp | $853.00 | 0.99% | 857,600 | +490,500 | +133.62% | 2025-09-30 |
| Millennium Management Llc | $740.00 | 0.86% | 743,781 | -68,432 | -8.43% | 2025-09-30 |